Mohamed Ehab Ali

Dr. Mohamed Ehab Ali

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
MAMohamed Ehab Ali
Mohamed Ehab Ali
Alf LamprechtAlf Lamprecht
Alf Lamprecht

1 October 2017 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
John YoushiaJohn Youshia
John Youshia
MAMohamed Ehab Ali
Mohamed Ehab Ali
Alf LamprechtAlf Lamprecht
Alf Lamprecht

1 January 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MAMohamed Ehab Ali
Mohamed Ehab Ali
ALAlf Lamprecht
Alf Lamprecht

1 November 2013 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MAMohamed Ehab Ali
Mohamed Ehab Ali
ALAlf Lamprecht
Alf Lamprecht

23 December 2014 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
MAMohamed Ehab Ali
Mohamed Ehab Ali
JMJason T McConville
Jason T McConville
Alf LamprechtAlf Lamprecht
Alf Lamprecht
Respiratory infections and diseases are accompanied by or exhibit inflammation. Recent advances in nanoparticle engineering technology, together with the increased knowledge of inflammatory pathophysiology, have ignited interest in the pulmonary delivery of anti-inflammatory agents (AIAs) to achieve local treatment of pulmonary inflammatory disorders. This review summarizes and discusses the investigated formulation approaches for the pulmonary delivery of AIAs, including: inhalation of actives as suspensions or dry powder formulations, with polymeric micro- and nano-delivery carriers, or within liposomes and lipid nanoparticles. Some recent approaches for targeting AIAs to the pulmonary endothelium have also been reviewed. The discussion focuses on finding out whether the investigated approaches were really able to achieve lung targeting and reduce the side effects associated with the systemic administration of AIAs. The use of the inhalation route for the pulmonary delivery of AIAs is facing several challenges. Some of the investigated formulation approaches appear to be promising in overcoming these challenges. However, in order to create products that reach patients, more therapeutically oriented studies are still needed to ensure formulation stability, in-vivo sustained release behavior, pulmonary retention, and bypassing lung clearance mechanisms.

1 February 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MTMuhammad Azam Tahir
Muhammad Azam Tahir
MAMohamed Ehab Ali
Mohamed Ehab Ali
ALAlf Lamprecht
Alf Lamprecht